title: Three new drugs for multiple myeloma.
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000037:antagonists & inhibitors / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001896:Boron Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000401:mortality; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects / Q000276:immunology; D061988:Proteasome Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000037:antagonists & inhibitors / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001896:Boron Compounds; D008562:Membrane Glycoproteins; D061988:Proteasome Inhibitors; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab; C556306:daratumumab; C548400:ixazomib; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D046988:Proteasome Endopeptidase Complex; D005998:Glycine